A
Alan Ashworth
Researcher at University of California, San Francisco
Publications - 589
Citations - 82138
Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.
Papers
More filters
Journal ArticleDOI
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Alan Mackay,Ander Urruticoechea,J. Michael Dixon,Tim Dexter,Kerry Fenwick,Alan Ashworth,Suzanne C. Drury,Alexey Larionov,O. Young,Sharon A. White,William R. Miller,Dean B. Evans,Mitch Dowsett,Mitch Dowsett +13 more
TL;DR: These findings identify the transcriptional signatures associated with aromatase inhibitor treatment of primary breast tumours and should enable identification of estrogen-dependent molecular changes, which are the determinants of benefit or resistance to endocrine therapy.
Journal ArticleDOI
Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study
Danielle H. Bodicoat,Danielle H. Bodicoat,Danielle H. Bodicoat,Minouk J. Schoemaker,Michael Jones,Emily McFadden,Emily McFadden,James Griffin,Alan Ashworth,Anthony J. Swerdlow,Anthony J. Swerdlow +10 more
TL;DR: Breast duct development may be a time of heightened susceptibility to risk of carcinogenesis, and greater attention needs to be given to the relation of breast cancer risk to the different stages of puberty.
Journal ArticleDOI
Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
Ana M. Mendes-Pereira,David Sims,Tim Dexter,Kerry Fenwick,Ioannis Assiotis,Iwanka Kozarewa,Costas Mitsopoulos,Jarle Hakas,Marketa Zvelebil,Christopher J. Lord,Alan Ashworth +10 more
TL;DR: Combining whole-genome shRNA screening with massively parallel sequencing, this work has profiled the impact of more than 56,670 RNA interference reagents targeting 16,487 genes on the cellular response to tamoxifen.
Journal ArticleDOI
Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse
Rachael Natrajan,Richard Williams,Sandra Hing,Alan Mackay,Jorge S. Reis-Filho,Kerry Fenwick,Marjan Iravani,Haukur Valgeirsson,Anita Grigoriadis,Cordelia Langford,Oliver M. Dovey,Simon G. Gregory,Barbara L. Weber,Alan Ashworth,Paul E. Grundy,Kathy Pritchard-Jones,Chris Jones +16 more
TL;DR: Using 1Mb‐spaced genome‐wide BAC arrays, the most significantly different genomic changes between favourable histology tumours that did not relapse, and did not, subsequently relapse were gains on 1q, and novel deletions at 12q24 and 18q21, respectively.
Journal ArticleDOI
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Elizabeth Iorns,Christopher J. Lord,A Grigoriadis,Sarah McDonald,Kerry Fenwick,Alan Mackay,Charles A. Mein,Rachael Natrajan,Kay Savage,Narinder Tamber,Jorge S. Reis-Filho,Nicholas C. Turner,Alan Ashworth +12 more
TL;DR: A novel approach combining RNAi screening in multiple cell lines with gene expression and genomic profiling to identify novel cancer targets, allowing the identification of several novel kinases, including WEE1, that are essential for viability only in cell lines that have an elevated level of expression of this kinase.